Bamlanivimab Plus Etesevimab Cuts COVID-19 Hospitalization, Deaths
The combination therapy reduced the risk of hospitalization or death by 70%.
The combination therapy reduced the risk of hospitalization or death by 70%.
The study was conducted by Pfizer and the University of Texas Medical Branch.
An expert panel assessed 39 diets to come up with the final results, examining the evidence behind each diet’s claims.
The counterfeit products were procured from unauthorized distributors.
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
The JADE REGIMEN trial was a responder-enriched, placebo-controlled withdrawal study that included a 12-week open-label run-in period.
An interim analysis of the phase 2 study evaluated the combination therapy in recently diagnosed patients with mild to moderate COVID-19.
In a statement, the Company noted that the actions being taken are considered “routine” when an unexplained illness is reported in a clinical trial.
Previously, the EUA limited use to patients with severe COVID-19 disease.
The EUA was based on historical evidence indicating some effectiveness with convalescent plasma use in previous outbreaks of respiratory viruses, preclinical data, results from small clinical trials, and data from the National Expanded Access Treatment Protocol sponsored by the Mayo Clinic.